4.6 Article

Preoperative Hydronephrosis Predicts Extravesical and Node Positive Disease in Patients Undergoing Cystectomy for Bladder Cancer

期刊

JOURNAL OF UROLOGY
卷 183, 期 5, 页码 1732-1737

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.juro.2010.01.028

关键词

urinary bladder neoplasms; cystectomy; hydronephrosis; neoplasm staging; mortality

资金

  1. Sanofi-Aventis
  2. Allergen
  3. Watson
  4. GlaxoSmithKline
  5. GTX
  6. Endo and Firmagen
  7. Furring

向作者/读者索取更多资源

Purpose: Preoperative hydronephrosis may be associated with a worse outcome in patients who undergo radical cystectomy for invasive bladder cancer. We characterized the prognostic significance of hydronephrosis, and its relationship to cancer stage and outcome. We also evaluated concordance between the side of identifiable hydronephrosis and concomitant pelvic lymph node metastasis. Materials and Methods: We analyzed information from our prospectively collected database of patients who underwent radical cystectomy for bladder cancer from January 2001 to December 2007. We examined the relationship between hydronephrosis and clinical variables as well as survival outcome. Hydronephrosis was diagnosed intraoperatively or by radiographic imaging within 3 months of radical cystectomy. Results: Of 753 patients 244(32%) were diagnosed with hydronephrosis. Logistic regression modeling revealed that hydronephrosis was an independent predictor of extravesical disease (OR 2.01, 95% CI 1.37 to 2.96, p < 0.001) and node positive disease (OR 1.94, 95% CI 1.29 to 2.91, p = 0.001). Of patients with hydronephrosis 88 (36.1%) had concomitant node positive disease and 74 (30.3%) had node positive disease on the same side as hydronephrosis. Thus, hydronephrosis predicted the side of nodal involvement in 74 of 88 patients (84%) with identifiable hydronephrosis and node positive disease. Conclusions: Hydronephrosis is an independent predictor of advanced bladder cancer stage, and it predicts extravesical disease and node positive disease. Thus, it could prove useful to select patients for neoadjuvant chemotherapy before surgery. The strong correlation between hydronephrosis side and nodal metastasis may have implications for surgical staging and approach.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

PTEN expression and morphological patterns in prostatic adenocarcinoma

Andrew J. Spieker, Jennifer B. Gordetsky, Alexander S. Maris, Lauren M. Dehan, James E. Denney, Shanna A. Arnold Egloff, Kristen Scarpato, Daniel A. Barocas, Giovanna A. Giannico

Summary: This study investigated the association between PTEN expression and morphological patterns in prostate cancer, revealing that PTEN loss within glomeruloid morphology was associated with biochemical recurrence. Despite PTEN loss not being significantly associated with invasive cribriform carcinoma, the presence of any cribriform pattern was linked to biochemical recurrence.

HISTOPATHOLOGY (2021)

Editorial Material Urology & Nephrology

Factors Associated With Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort

Lauren Folgosa Cooley, Adaeze A. Emeka, Travis J. Meyers

JOURNAL OF UROLOGY (2021)

Article Urology & Nephrology

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer

David D'Andrea, Peter C. Black, Homayoun Zargar, Colin P. Dinney, Francesco Soria, Michael S. Cookson, Jeffrey S. Montgomery, Wassim Kassouf, Marc A. Dall'Era, Srikala S. Sridhar, John S. McGrath, Jonathan L. Wright, Andrew C. Thorpe, Jeff M. Holzbeierlein, Diego M. Carrion, Ettore Di Trapani, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, Yair Lotan, Petros Grivas, Andrew J. Stephenson, Bas W. van Rhijn, Siamak Daneshmand, Philippe E. Spiess, Shahrokh F. Shariat, Kamran Zargar-Shoshtar, Laura S. Mertens, Adrian S. Fairey, Maria C. Mir, Laura-Maria Krabbe, Niels-Erik Jacobsen, Nikhil Vasdev, Evan Y. Yu, Evanguelos Xylinas, Benjamin Pradere, Renate Pichler, Nicholas J. Campain, Jo-An Seah, Cesar E. Ercole, Simon Horenblas, Jonathan Aning, Todd M. Morgan, Jay B. Shah, Marco Moschini

Summary: This study investigated the pathological response rates and survival outcomes of patients with cT2-4N0M0 muscle invasive bladder cancer who received 3 vs 4 cycles of cisplatin-based neoadjuvant chemotherapy (NAC). The results showed that patients treated with 4 cycles of NAC achieved better pathological response and overall survival compared to those treated with 3 cycles. These findings provide valuable information for clinicians and serve as a benchmark for prospective trials.

JOURNAL OF UROLOGY (2022)

Article Oncology

Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function

Daniel D. Joyce, Christopher J. D. Wallis, Amy N. Luckenbaugh, Heather L. Huelster, Zhiguo Zhao, Karen E. Hoffman, Li-Ching Huang, Tatsuki Koyama, Ralph Conwill, Michael Goodman, Ann S. Hamilton, Xiao-Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B. O'Neil, Sherrie H. Kaplan, Sheldon Greenfield, David F. Penson, Daniel A. Barocas

Summary: The addition of androgen deprivation therapy in combination with radiation treatment is associated with worse sexual function through 3 years in men with high-risk prostate cancer compared to radiation alone. However, adding androgen deprivation therapy in the treatment of intermediate-risk disease does not lead to worse sexual function at 3 or 5-year follow-up compared to radiation alone.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Article Oncology

Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort

Christopher J. D. Wallis, Li-Ching Huang, Zhiguo Zhao, David F. Penson, Tatsuki Koyama, Ralph Conwill, Jacob E. Tallman, Michael Goodman, Ann S. Hamilton, Xiao-Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B. O'Neil, Sherrie H. Kaplan, Sheldon Greenfield, Daniel A. Barocas, Karen E. Hoffman

Summary: This population-based cohort study compared the functional outcomes of men receiving prostate and pelvic radiotherapy versus prostate-only radiotherapy over a 5-year period. The results showed that men receiving prostate and pelvic radiotherapy reported worse sexual, hormonal, and physical function compared to those receiving prostate-only radiotherapy. However, there were no statistically or clinically significant differences in bowel function, urinary incontinence, irritative voiding symptoms, or sexual function between the two groups.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Urology & Nephrology

Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

David D'Andrea, Peter C. Black, Homayoun Zargar, Kamran Zargar-Shoshtari, Francesco Soria, Adrian S. Fairey, Laura S. Mertens, Colin P. Dinney, Maria C. Mir, Laura-Maria Krabbe, Michael S. Cookson, Niels-Erik Jacobsen, Jeffrey S. Montgomery, Nikhil Vasdev, Evan Y. Yu, Evanguelos Xylinas, Nicholas J. Campain, Wassim Kassouf, Marc A. Dall'Era, Jo-An Seah, Cesar E. Ercole, Simon Horenblas, Srikala S. Sridhar, John S. McGrath, Jonathan Aning, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, Yair Lotan, Petros Grivas, Andrew J. Stephenson, Jay B. Shah, Bas W. van Rhijn, Siamak Daneshmand, Philippe E. Spiess, Shahrokh F. Shariat

Summary: The study evaluated the association of patient age with response to preoperative chemotherapy in MIBC patients. Younger patients showed slightly lower DDR gene mutations but no significant difference in treatment response or survival outcomes based on age. The findings suggest that preoperative chemotherapy should be considered regardless of patient age.

WORLD JOURNAL OF UROLOGY (2021)

Article Urology & Nephrology

Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes

Amy N. Luckenbaugh, Christopher J. D. Wallis, Li-Ching Huang, Daniela Wittmann, Zachary Klaassen, Zighuo Zhao, Tatsuki Koyama, Aaron A. Laviana, Ralph Conwill, Michael Goodman, Ann S. Hamilton, Xiao-Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B. O'Neil, Sherrie H. Kaplan, Sheldon Greenfield, Karen E. Hoffman, David F. Penson, Daniel A. Barocas

Summary: The study aimed to compare the patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer over a 5-year period. The results showed that there were no clinically significant differences in mental health outcomes, including depressive symptoms, emotional well-being, and energy/fatigue, based on the treatment received (surgery, radiotherapy, or surveillance). However, certain factors like older age, poorer health, being unmarried, and baseline depressive symptoms were associated with worse mental health outcomes.

JOURNAL OF UROLOGY (2022)

Article Urology & Nephrology

Association Between Surgical Volume and Survival Among Patients With Variant Histologies of Bladder Cancer

Wilson Sui, Mary E. Hall, Daniel A. Barocas, Sam S. Chang, Amy N. Luckenbaugh, Kelvin A. Moses, David F. Penson, Christopher J. D. Wallis, Aaron A. Laviana

Summary: The study reveals that the management of bladder cancer variant histology at high-volume centers is associated with improved overall survival. Hospital volume and/or surgeon volume are related to the management of rare or complex diseases, and can affect treatment patterns.

UROLOGY (2022)

Article Oncology

Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer

Christopher J. D. Wallis, Zhiguo Zhao, Li-Ching Huang, David F. Penson, Tatsuki Koyama, Sherrie H. Kaplan, Sheldon Greenfield, Amy N. Luckenbaugh, Zachary Klaassen, Ralph Conwill, Michael Goodman, Ann S. Hamilton, Xiao-Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B. O'Neil, Karen E. Hoffman, Daniel A. Barocas

Summary: Treatment-related regret is a common experience for localized prostate cancer patients, with rates differing depending on treatment approach, functional outcomes, and patient expectations. Patient-perceived treatment efficacy and adverse effects, along with functional outcomes like sexual dysfunction, were significant factors associated with regret. Shared decision-making tools, social support, and age also played a role in predicting treatment-related regret.

JAMA ONCOLOGY (2022)

Article Medicine, General & Internal

Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence A Secondary Analysis of a Randomized Clinical Trial

Vivek Venkatramani, Isildinha M. Reis, Mark L. Gonzalgo, Erik P. Castle, Michael E. Woods, Robert S. Svatek, Alon Z. Weizer, Badrinath R. Konety, Mathew Tollefson, Tracey L. Krupski, Norm D. Smith, Ahmad Shabsigh, Daniel A. Barocas, Marcus L. Quek, Atreya Dash, Dipen J. Parekh

Summary: This study aimed to determine the recovery of functional independence after radical cystectomy and compare the differences between robot-assisted radical cystectomy (RARC) and open procedures. The results showed that patients require 3 to 6 months to recover baseline levels, regardless of the surgical approach. Hand grip strength and activities of daily living tend to recover earlier after RARC, but there was no difference in the percentage of patients recovering compared to open procedures. These findings are important for patient counseling and preparation.

JAMA NETWORK OPEN (2022)

Correction Urology & Nephrology

Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium (vol 7, pg 1347, 2021)

Maria Carmen Mir, Michele Marchionic, Homi Zargard, K. Zargar-Shoshtari, A. S. Fairey, Laura S. Mertens, C. P. Dinney, L. M. Krabbei, M. S. Cookson, N. E. Jacobsen, J. Griffin, J. S. Montgomery, N. Vasdev, E. Y. Yu, E. Xylinas, J. S. McGrathr, W. Kassoufs, M. A. Dall'Era, S. S. Sridhar, J. Aningn, S. F. Shariat, J. L. Wright, A. C. Thorpe, T. M. Morganm, J. M. Holzbeierlein, T. J. Bivalacquax, S. North, D. A. Barocas, Y. Lotan, P. Grivaso, A. J. Stephenson, J. B. Shah, B. W. van Rhijng, P. E. Spiess, S. Daneshmand, P. C. Blackd

EUROPEAN UROLOGY FOCUS (2022)

Article Oncology

Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer

Jacob E. Tallman, Christopher J. D. Wallis, Li-Ching Huang, Zhiguo Zhao, David F. Penson, Tatsuki Koyama, Ralph Conwill, Michael Goodman, Ann S. Hamilton, Xiao-Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B. O'Neil, Sherrie H. Kaplan, Sheldon Greenfield, Daniel A. Barocas, Karen E. Hoffman

Summary: Compliance with nationally recognized radiation therapy quality measures was not significantly associated with patient-reported health-related quality of life outcomes after prostate cancer treatment.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare

Brian D. Cortese, Stacie B. Dusetzina, Amy N. Luckenbaugh, Bashir Al Hussein Al Awamlh, C. J. Stimson, Daniel A. Barocas, David F. Penson, Sam S. Chang, Ruchika Talwar

Summary: This study estimated the potential savings of using Mark Cuban Cost Plus Drug Company (MCCPDC) prices for seven generic oncology drugs in Medicare Part D plans. The findings suggest significant cost savings could be achieved by replacing current Part D formulary prices with MCCPDC pricing.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Genetics & Heredity

Genetic factors associated with prostate cancer conversion from active surveillance to treatment

Yu Jiang, Travis J. Meyers, Adaeze A. Emeka, Lauren Folgosa Cooley, Phillip R. Cooper, Nicola Lancki, Irene Helenowski, Linda Kachuri, Daniel W. Lin, Janet L. Stanford, Lisa F. Newcomb, Suzanne Kolb, Antonio Finelli, Neil E. Fleshner, Maria Komisarenko, James A. Eastham, Behfar Ehdaie, Nicole Benfante, Christopher J. Logothetis, Justin R. Gregg, Cherie A. Perez, Sergio Garza, Jeri Kim, Leonard S. Marks, Merdie Delfin, Danielle Barsa, Danny Vesprini, Laurence H. Klotz, Andrew Loblaw, Alexandre Mamedov, S. Larry Goldenberg, Celestia S. Higano, Maria Spillane, Eugenia Wu, H. Ballentine Carter, Christian P. Pavlovich, Mufaddal Mamawala, Tricia Landis, Peter R. Carroll, June M. Chan, Matthew R. Cooperberg, Janet E. Cowan, Todd M. Morgan, Javed Siddiqui, Rabia Martin, Eric A. Klein, Karen Brittain, Paige Gotwald, Daniel A. Barocas, Jeremiah R. Dallmer, Jennifer B. Gordetsky, Pam Steele, Shilajit D. Kundu, Jazmine Stockdale, Monique J. Roobol, Lionne D. F. Venderbos, Martin G. Sanda, Rebecca Arnold, Dattatraya Patil, Christopher P. Evans, Marc A. Dall'Era, Anjali Vij, Anthony J. Costello, Ken Chow, Niall M. Corcoran, Soroush Rais-Bahrami, Courtney Phares, Douglas S. Scherr, Thomas Flynn, R. Jeffrey Karnes, Michael Koch, Courtney Rose Dhondt, Joel B. Nelson, Dawn McBride, Michael S. Cookson, Kelly L. Stratton, Stephen Farriester, Erin Hemken, Walter M. Stadler, Tuula Pera, Deimante Banionyte, Fernando J. Bianco, Isabel H. Lopez, Stacy Loeb, Samir S. Taneja, Nataliya Byrne, Christopher L. Amling, Ann Martinez, Luc Boileau, Franklin D. Gaylis, Jacqueline Petkewicz, Nicholas Kirwen, Brian T. Helfand, Jianfeng Xu, Denise M. Scholtens, William J. Catalona, John S. Witte

Summary: Men diagnosed with low-risk prostate cancer who initially choose active surveillance may eventually convert to active treatment due to genetic factors that predispose to aggressive tumors. This study identified genetic variants associated with conversion from active surveillance to active treatment, suggesting that germline genetics may help individualize management decisions for low-risk prostate cancer.

HUMAN GENETICS AND GENOMICS ADVANCES (2022)

Article Oncology

Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma

Melih Balci, Zachary A. Glaser, Sam S. Chang, S. Duke Herrell, Daniel A. Barocas, Kirk A. Keegan, Kelvin A. Moses, Matthew J. Resnick, Joseph A. Smith, David F. Penson, Kristen Scarpato, Peter E. Clark

Summary: The study investigated the relationship between gender, BMI, and prognosis in renal cell carcinoma patients. Higher BMI was associated with better overall survival and recurrence-free survival, especially in male patients. Female patients did not show a significant relationship between BMI and oncologic outcomes.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2021)

暂无数据